Zentalis Pharmaceuticals' (ZNTL) "Neutral" Rating Reaffirmed at Wedbush

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report)'s stock had its "neutral" rating reissued by research analysts at Wedbush in a research note issued on Friday,RTT News reports. They presently have a $4.00 price objective on the stock. Wedbush's price target points to a potential upside of 80.18% from the company's current price.

ZNTL has been the topic of a number of other reports. Guggenheim dropped their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Zentalis Pharmaceuticals has a consensus rating of "Hold" and an average target price of $10.00.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL traded down $0.08 during trading on Friday, hitting $2.22. The stock had a trading volume of 2,468,833 shares, compared to its average volume of 2,124,194. The stock has a market capitalization of $158.20 million, a price-to-earnings ratio of -0.89 and a beta of 1.86. The stock has a 50 day simple moving average of $3.07 and a 200 day simple moving average of $3.36. Zentalis Pharmaceuticals has a one year low of $2.13 and a one year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.36. On average, sell-side analysts predict that Zentalis Pharmaceuticals will post -2.48 EPS for the current year.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Erste Asset Management GmbH purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth about $37,000. Paloma Partners Management Co acquired a new stake in Zentalis Pharmaceuticals in the 3rd quarter valued at about $37,000. Aigen Investment Management LP purchased a new position in Zentalis Pharmaceuticals in the 3rd quarter worth approximately $41,000. Capstone Investment Advisors LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $48,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company's stock worth $50,000 after purchasing an additional 5,333 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.